Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last month ...
Hosted on MSN1mon
Biogen Wants to Buy Its Partner Sage for Almost No PremiumShares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.
As it waits for its Alzheimer’s drug verdict, Biogen stumps up $1.5bn-plus upfront for rights to Sage drugs zuranolone for depression and SAGE-324 for essential tremor ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a $469 million offer from Biogen it said “significantly ...
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday while also sharing more details on the internal culling of its R&D pipeline ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results